Last reviewed · How we verify

Affymax — Portfolio Competitive Intelligence Brief

Affymax pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Epoetin alfa or Epoetin beta Epoetin alfa or Epoetin beta phase 3 Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology/Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amgen · 1 shared drug class
  2. Anemia Working Group Romania · 1 shared drug class
  3. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  4. Australian and New Zealand Intensive Care Research Centre · 1 shared drug class
  5. Barts & The London NHS Trust · 1 shared drug class
  6. Bio Sidus SA · 1 shared drug class
  7. Biocad · 1 shared drug class
  8. Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Affymax:

Cite this brief

Drug Landscape (2026). Affymax — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/affymax. Accessed 2026-05-15.

Related